 Connection
Diana Medgyesy to Humans
This is a "connection" page, showing publications Diana Medgyesy has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.008 |
|
|
|
-
Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res. 2013 May 15; 19(10):2745-54.
Score: 0.002
-
Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res. 2003 Jan; 9(1):134-42.
Score: 0.001
-
Royce ME, Medgyesy D, Zukowski TH, Dwivedy S, Hoff PM, Pazdur R. Colorectal cancer: chemotherapy treatment overview. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):40-6.
Score: 0.001
-
Hoff PM, Royce M, Medgyesy D, Brito R, Pazdur R. Oral fluoropoyrimidines. Semin Oncol. 1999 Dec; 26(6):640-6.
Score: 0.001
-
Brito RA, Medgyesy D, Zukowski TH, Royce ME, Ravandi-Kashani F, Hoff PM, Pazdur R. Fluoropyrimidines: a critical evaluation. Oncology. 1999 Jul; 57 Suppl 1:2-8.
Score: 0.001
-
Pazdur R, Hoff PM, Medgyesy D, Royce M, Brito R. The oral fluorouracil prodrugs. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):48-51.
Score: 0.001
-
Pazdur R, Medgyesy DC, Winn RJ, Dakhil SR, Moore DF, Scalzo A, Hoff PM, Arbuck SG, Abbruzzese JL. Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma. Invest New Drugs. 1998-1999; 16(4):341-6.
Score: 0.001
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|